OMRON (6645) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
5 Feb, 2026Executive summary
Consolidated revenue increased year-over-year in Q3 FY2025, but profits declined due to a lower gross profit margin and continued growth investments; net sales for the nine months ended December 31, 2025, increased 6.0% YoY to JPY614.3 billion, with operating income down 5.7% to JPY33.9 billion, both exceeding initial projections.
Net income attributable to shareholders nearly doubled year-over-year to JPY14.3 billion, reflecting the absence of prior-year one-time restructuring expenses.
IAB segment saw significant revenue growth, driven by AI-related demand and customer base recovery.
Gross profit margin declined by 1.3 points to 43.9% due to higher raw material and logistics costs and U.S. tariff impacts.
Comprehensive income surged 113.9% year-over-year, driven by strong foreign currency translation adjustments.
Financial highlights
Q3 FY2025 net sales rose 7.7% YoY to ¥220.8bn; gross profit up 5.7% YoY to ¥97.0bn.
Q3 operating income fell 3.2% YoY to ¥16.1bn; net income attributable to shareholders dropped 49.6% YoY to ¥5.3bn.
Cumulative Q1–Q3 FY2025 net sales up 6.0% YoY to JPY614.3 billion; operating income down 5.7% YoY to JPY33.9 billion.
Full-year FY2025 revenue forecast revised to ¥855.0bn (+6.6% YoY); operating income forecast at ¥60.0bn (+11.0% YoY).
Net income for FY2025 projected at ¥29.0bn (+78.2% YoY); EPS forecast at ¥147.40.
Outlook and guidance
Q4 expected to see significant profit growth, driven by revenue growth and margin improvement, especially in IAB.
Dividend per share guidance maintained at ¥52 for year-end and ¥104 for the full year.
Operating margin expected to improve in Q4, returning to profit growth.
Capital investment demand for generative AI-related expected to remain strong; EV-related demand sluggish.
Healthcare demand in China expected to remain flat; renewable energy market to see temporary lull.
Latest events from OMRON
- Sales up 5%, profit guidance raised as automation and data outperform, healthcare lags.6645
Q2 202619 Nov 2025 - Net income rebounded to ¥6.8bn as automation and device growth offset healthcare weakness.6645
Q1 20266 Aug 2025 - Sales and profit fell sharply on restructuring costs, but full-year outlook is maintained.6645
Q1 202513 Jun 2025 - Full-year profit guidance raised and dividends maintained despite lower sales and restructuring costs.6645
Q2 202513 Jun 2025 - Profits surged on margin gains; FY2025/26 outlook cautious amid tariff risks.6645
Q4 20259 Jun 2025 - Profit outlook raised as margin gains offset sales drop and restructuring costs.6645
Q3 20259 Jun 2025